New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
10:28 EDTVRTX, KPTI, EBKDY, VSTM, ZINC, ZBRA, TFM, HOS, BRKR, BECNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Beacon Roofing (BECN) downgraded to Market Perform from Outperform at William Blair... Bruker (BRKR) downgraded to Neutral from Buy at ISI Group... Erste Group Bank (EBKDY) downgraded to Hold from Buy at Deutsche Bank... Hornbeck Offshore (HOS) downgraded to Equal Weight from Overweight at Stephens... Horsehead Holding (ZINC) downgraded to Market Perform at FBR Capital... Karyopharm (KPTI) downgraded to Perform from Outperform at Oppenheimer... The Fresh Market (TFM) downgraded to Sell from Neutral at Goldman... Verastem (VSTM) downgraded to Perform from Outperform at Oppenheimer... Vertex (VRTX) downgraded to Perform from Outperform at Oppenheimer... Zebra Technologies (ZBRA) downgraded to In-Line from Outperform at Imperial Capital.
News For BECN;BRKR;EBKDY;HOS;ZINC;KPTI;TFM;VSTM;VRTX;ZBRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 28, 2015
16:07 EDTVRTXVertex sees FY15 KALYDECO net revenues $560M-$580M
FY15 revenue consensus $1.19B. KALYDECO net revenues reflect use of KALYDECO by eligible patients in Australia following the completion of reimbursement discussions in late 2014; use of KALYDECO in some people in the United States with the R117H mutation following FDA approval in late 2014; the completion of reimbursement discussions for gating mutations in certain European countries; and use of KALYDECO in children with CF ages 2 to 5 with the G551D or other gating mutations in the United States, based on potential approval in March 2015. Vertex expects that its combined non-GAAP R&D and SG&A expenses in 2015 will be in the range of $1.05B-$1.1B. The increase as compared to 2014 is primarily a result of launch preparation activities for lumacaftor in combination with ivacaftor and the planned pivotal Phase 3 development program for VX-661 in combination with ivacaftor.
16:05 EDTVRTXVertex reports Q4 adjusted EPS (55c), consensus (65c)
Reports Q4 revenue $145M, consensus $137.49M. Reports Q4 revenues of $124M from KALYDECO in CF.
15:37 EDTVRTXNotable companies reporting after market close
Subscribe for More Information
January 26, 2015
09:14 EDTVSTMVerastem price target lowered to $23 from $29 at Roth Capital
Subscribe for More Information
January 23, 2015
10:02 EDTTFMOn the Fly: Analyst Initiation Summary
Subscribe for More Information
06:17 EDTVSTMVerastem Secondary increased to 7.25M shares, priced at $6.50
The deal size was increased to 7.25M shares from 4.5M shares. Jefferies and Leerink acted as joint book running managers for the offering.
January 22, 2015
18:31 EDTZINCHorsehead Holding 5M share Secondary priced at $12.75
Stifel acted as lead book running manager for the offering.
16:24 EDTTFMThe Fresh Market initiated with a Neutral at Wedbush
Subscribe for More Information
10:03 EDTTFMOn the Fly: Analyst Initiation Summary
Subscribe for More Information
07:30 EDTTFMThe Fresh Market initiated with a Market Perform at Cowen
Subscribe for More Information
January 21, 2015
08:03 EDTZBRAZebra Technologies' WLAN deployed in NYC subways
Zebra Technologies' wireless local area network technology is being used by the New York City Metropolitan Transportation Authority and Transit Wireless to deliver Wi-Fi connectivity service to the subway system. Transit Wireless is deploying a massive WLAN system in New York City's underground subway stations.
January 20, 2015
16:04 EDTVSTMVerastem files to sell $40M in common stock
Subscribe for More Information
16:01 EDTZINCHorsehead Holding files to sell 5M shares of common stock
Subscribe for More Information
08:11 EDTKPTIKaryopharm weakness unjustified, says JMP Securities
Subscribe for More Information
08:04 EDTVSTMVerastem receives orphan medicinial product designation from EC for VS-5584
Subscribe for More Information
07:05 EDTVSTMVerastem doses first patient in Phase 1 VS-5584 trial
Subscribe for More Information
January 16, 2015
07:03 EDTVSTMVerastem announces publication of scientific data for VS-5584 in cancer research
Verastem announced that a paper, titled “PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells,” has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research. The paper discusses results from preclinical research evaluating VS-5584, a highly potent, selective small molecule inhibitor of mTORC1/2 and Class I PI3K kinases, which preferentially targets cancer stem cells in vitro and in vivo. CSCs represent a subpopulation of cancer cells that have tumor-initiating capability, are particularly resistant to chemotherapy and can mediate tumor recurrence both locally and at metastatic sites. The study results demonstrated that VS-5584 is up to 30-fold more potent in inhibiting the proliferation and survival of CSCs compared to non-CSCs in solid tumor cell populations. VS-5584 preferentially diminished CSC levels in multiple mouse xenograft models of human cancer. Similarly, VS-5584 treatment ex vivo preferentially reduced CSCs in surgically resected breast and ovarian patient tumors. In contrast, chemotherapeutics such as paclitaxel, cisplatin and etoposide effectively targeted bulk tumor cells, but enriched CSCs. Mechanistic investigations revealed that knock down of PI3Kα, PI3Kβ or mTOR alone was insufficient to decrease CSCs, while knock down of PI3Kα, PI3Kβ and mTOR together effectively reduced CSCs mimicking the effect of VS-5584. Consistent with CSC ablation, VS-5584 delayed tumor regrowth following chemotherapy in xenograft models of small cell lung cancer. These data help to elucidate the mechanism of VS-5584 targeting CSCs and provide a strong rationale for the clinical development of VS-5584 in combination with chemotherapeutic agents targeting bulk tumor cells to achieve more durable clinical responses in cancer patients.
05:39 EDTVSTMVerastem risk/reward favorable after pullback, says Mizuho
Subscribe for More Information
January 15, 2015
05:55 EDTVSTMVerastem has meeting hosted by Philadelphia Securities Association
Luncheon Meeting to be held in Philadelphia at 11:30 am on January 15 hosted by Philadelphia Securities Association.
05:55 EDTTFMSupermarkets upgraded to Neutral from Cautious at Goldman Sachs
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use